Literature DB >> 33362721

Oxidation-Specific Epitopes in Non-Alcoholic Fatty Liver Disease.

Tim Hendrikx1,2, Christoph J Binder2,3.   

Abstract

An improper balance between the production and elimination of intracellular reactive oxygen species causes increased oxidative stress. Consequently, DNA, RNA, proteins, and lipids are irreversibly damaged, leading to molecular modifications that disrupt normal function. In particular, the peroxidation of lipids in membranes or lipoproteins alters lipid function and promotes formation of neo-epitopes, such as oxidation-specific epitopes (OSEs), which are found to be present on (lipo)proteins, dying cells, and extracellular vesicles. Accumulation of OSEs and recognition of OSEs by designated pattern recognition receptors on immune cells or soluble effectors can contribute to the development of chronic inflammatory diseases. In line, recent studies highlight the involvement of modified lipids and OSEs in different stages of the spectrum of non-alcoholic fatty liver disease (NAFLD), including inflammatory non-alcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma. Targeting lipid peroxidation products shows high potential in the search for novel, better therapeutic strategies for NASH.
Copyright © 2020 Hendrikx and Binder.

Entities:  

Keywords:  innate immunity; lipid peroxidation; non-alcoholic fatty liver disease; oxidation-specific epitopes; oxidative stress; steatohepatitis (NASH)

Mesh:

Substances:

Year:  2020        PMID: 33362721      PMCID: PMC7756077          DOI: 10.3389/fendo.2020.607011

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


  100 in total

1.  Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.

Authors:  J E Lavine
Journal:  J Pediatr       Date:  2000-06       Impact factor: 4.406

Review 2.  Oxidation-specific epitopes are major targets of innate immunity in atherothrombosis.

Authors:  Barbara Bartolini Gritti; Christoph J Binder
Journal:  Hamostaseologie       Date:  2015-02-16       Impact factor: 1.778

3.  Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice.

Authors:  Timea Csak; Arumugam Velayudham; Istvan Hritz; Jan Petrasek; Ivan Levin; Dora Lippai; Donna Catalano; Pranoti Mandrekar; Angela Dolganiuc; Evelyn Kurt-Jones; Gyongyi Szabo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-01-13       Impact factor: 4.052

Review 4.  Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view.

Authors:  Sara Thietart; Pierre-Emmanuel Rautou
Journal:  J Hepatol       Date:  2020-07-15       Impact factor: 25.083

5.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  N Engl J Med       Date:  2010-04-28       Impact factor: 91.245

Review 6.  Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins.

Authors:  Sofie M A Walenbergh; Ger H Koek; Veerle Bieghs; Ronit Shiri-Sverdlov
Journal:  J Hepatol       Date:  2012-11-23       Impact factor: 25.083

7.  Malondialdehyde epitopes are sterile mediators of hepatic inflammation in hypercholesterolemic mice.

Authors:  Clara Jana-Lui Busch; Tim Hendrikx; David Weismann; Sven Jäckel; Sofie M A Walenbergh; André F Rendeiro; Juliane Weißer; Florian Puhm; Anastasiya Hladik; Laura Göderle; Nikolina Papac-Milicevic; Gerald Haas; Vincent Millischer; Saravanan Subramaniam; Sylvia Knapp; Keiryn L Bennett; Christoph Bock; Christoph Reinhardt; Ronit Shiri-Sverdlov; Christoph J Binder
Journal:  Hepatology       Date:  2017-02-03       Impact factor: 17.425

Review 8.  Pharmacological Treatment for Non-alcoholic Fatty Liver Disease.

Authors:  Sven Francque; Luisa Vonghia
Journal:  Adv Ther       Date:  2019-03-19       Impact factor: 3.845

9.  A genome-wide association study identifies key modulators of complement factor H binding to malondialdehyde-epitopes.

Authors:  Lejla Alic; Nikolina Papac-Milicevic; Darina Czamara; Ramona B Rudnick; Maria Ozsvar-Kozma; Andrea Hartmann; Michael Gurbisz; Gregor Hoermann; Stefanie Haslinger-Hutter; Peter F Zipfel; Christine Skerka; Elisabeth B Binder; Christoph J Binder
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-22       Impact factor: 11.205

10.  Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease.

Authors:  Tim Hendrikx; Martin L Watzenböck; Sofie M A Walenbergh; Shahzada Amir; Sabrina Gruber; Maria Ozsvar Kozma; Heike I Grabsch; Ger H Koek; Marieke J Pierik; Katharina Staufer; Michael Trauner; Satish C Kalhan; Daisy Jonkers; Marten H Hofker; Christoph J Binder; Ronit Shiri-Sverdlov
Journal:  BMC Med       Date:  2016-07-22       Impact factor: 8.775

View more
  4 in total

Review 1.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

Review 2.  Oxidized Lipids: Common Immunogenic Drivers of Non-Alcoholic Fatty Liver Disease and Atherosclerosis.

Authors:  Constanze Hoebinger; Dragana Rajcic; Tim Hendrikx
Journal:  Front Cardiovasc Med       Date:  2022-01-10

3.  Association between bilirubin and nonalcoholic fatty liver disease in the non-obese Chinese population: a cross-sectional study.

Authors:  Xiaochuang Shu; Ya Zheng; Zhaofeng Chen; Qinghong Guo; Yuping Wang; Rui Ji; Yongning Zhou
Journal:  Ann Transl Med       Date:  2022-05

Review 4.  Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.

Authors:  Alvaro Santos-Laso; María Gutiérrez-Larrañaga; Marta Alonso-Peña; Juan M Medina; Paula Iruzubieta; María Teresa Arias-Loste; Marcos López-Hoyos; Javier Crespo
Journal:  Biomedicines       Date:  2021-12-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.